Columbia Care Inc
F:3LP
Columbia Care Inc
Columbia Care, Inc. engages in the cultivation, manufacture and provision of medical cannabis products and services. The company is headquartered in New York City, New York. The company went IPO on 2019-04-29. The firm is engaged cultivating, manufacturing and providing medical and adult use cannabis products and related services with licenses in over 18 the United States jurisdictions and the European Union (EU). The firm operates facilities including dispensaries and cultivation and manufacturing facilities. The firm operates as the original providers of medical cannabis in the United States and continues to deliver a patient-centered medicinal cannabis operation. The firm offers products spanning flower, edibles, oils, and tablets, and manufactures brands including Seed & Strain, Amber and Platinum Label Cannabidiol (CBD) products. The company develops products which comprised of a variety of medical and adult-use form factors, including but not limited to formulations, precision manufactured dosing and cannabis flower and flower-derived products.
Columbia Care, Inc. engages in the cultivation, manufacture and provision of medical cannabis products and services. The company is headquartered in New York City, New York. The company went IPO on 2019-04-29. The firm is engaged cultivating, manufacturing and providing medical and adult use cannabis products and related services with licenses in over 18 the United States jurisdictions and the European Union (EU). The firm operates facilities including dispensaries and cultivation and manufacturing facilities. The firm operates as the original providers of medical cannabis in the United States and continues to deliver a patient-centered medicinal cannabis operation. The firm offers products spanning flower, edibles, oils, and tablets, and manufactures brands including Seed & Strain, Amber and Platinum Label Cannabidiol (CBD) products. The company develops products which comprised of a variety of medical and adult-use form factors, including but not limited to formulations, precision manufactured dosing and cannabis flower and flower-derived products.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
